or Try an Advanced Search...

    Technical Analysis for BLUE - bluebird bio, Inc.

    Grade Last Price % Change Price Change
    F 0.29 -3.37% -0.01
    BLUE closed down 0.69 percent on Wednesday, November 20, 2024, on 57 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical BLUE trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish -3.37%
    Doji - Bullish? Reversal -3.37%
    New 52 Week Low Weakness -3.37%
    Wide Bands Range Expansion -3.37%
    Oversold Stochastic Weakness -3.37%
    New 52 Week Closing Low Bearish -4.03%
    180 Bearish Setup Bearish Swing Setup -4.03%
    Lower Bollinger Band Walk Weakness -4.03%
    New 52 Week Low Weakness -4.03%
    Wide Bands Range Expansion -4.03%
    Older End-of-Day Signals for BLUE ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 4 hours ago
    Down 2 % about 4 hours ago
    Down 1% about 4 hours ago
    New 52 Week Low about 4 hours ago
    Up 3% about 4 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    BLUE Chart by TradingView
    Basic chart:

    Profile

    bluebird bio, Inc. Description

    bluebird bio, Inc., a clinical-stage biotechnology company, focuses on the development, manufacture, and marketing of therapies to treat various human diseases. Its product candidates include Lenti-D to treat patients with childhood cerebral adrenoleukodystrophy (ALD), a hereditary neurological disorder, as well as for the treatment of adult cerebral ALD; and CAR T cells products for treating oncology diseases. The company's product candidates also comprise LentiGlobin vector for the treatment of ß-thalassemia, a hereditary blood disorder; and sickle cell diseases. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Rare Diseases Medical Genetics Dystrophy Human Diseases Summit Childhood Genetic Genealogy Sickle Cell Disease Thalassemia Iglo Oncology Diseases

    Is BLUE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 16 bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
    Nov 15 JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
    Nov 15 bluebird bio extends selloff as BofA and J.P. Morgan cut after Q3 results
    Nov 15 bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...
    Nov 14 bluebird bio says seeking more cash to achieve cash flow break-even
    Nov 14 bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Transcript
    Nov 14 Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates
    Nov 14 Earnings Snapshot: bluebird bio reports mixed Q3, Q4 revenue outlook below consensus
    Nov 14 Bluebird: Q3 Earnings Snapshot
    Nov 14 bluebird bio GAAP EPS of -$0.31 beats by $0.06, revenue of $10.61M misses by $8.07M
    See more BLUE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.53
    52 Week Low 0.29
    Average Volume 6,011,752
    200-Day Moving Average 0.90
    50-Day Moving Average 0.47
    20-Day Moving Average 0.42
    10-Day Moving Average 0.36
    Average True Range 0.04
    RSI (14) 23.66
    ADX 39.96
    +DI 6.08
    -DI 35.08
    Chandelier Exit (Long, 3 ATRs) 0.41
    Chandelier Exit (Short, 3 ATRs) 0.40
    Upper Bollinger Bands 0.55
    Lower Bollinger Band 0.29
    Percent B (%b) 0.06
    BandWidth 62.52
    MACD Line -0.05
    MACD Signal Line -0.04
    MACD Histogram -0.0104
    Fundamentals Value
    Market Cap 58.4 Million
    Num Shares 193 Million
    EPS -0.63
    Price-to-Earnings (P/E) Ratio -0.48
    Price-to-Sales 9.32
    Price-to-Book 0.89
    PEG Ratio 0.32
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.34
    Resistance 3 (R3) 0.34 0.33 0.34
    Resistance 2 (R2) 0.33 0.32 0.33 0.33
    Resistance 1 (R1) 0.32 0.31 0.31 0.32 0.33
    Pivot Point 0.30 0.30 0.30 0.30 0.30
    Support 1 (S1) 0.29 0.29 0.28 0.29 0.27
    Support 2 (S2) 0.28 0.29 0.28 0.27
    Support 3 (S3) 0.26 0.28 0.27
    Support 4 (S4) 0.26